Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Beam Therapeutics Inc (NQ: BEAM )

25.05 +1.47 (+6.23%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Beam Therapeutics Inc

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Biotech Bloodbath Continues Despite Gene-Editing Deals For Pfizer, Bayer
Pfizer and Bayer inked deals with several companies in gene-editing. 
Via Investor's Business Daily
Expert Ratings For Beam Therapeutics
Within the last quarter, Beam Therapeutics (NASDAQ:BEAM) has observed the f... 
Via Benzinga
Pfizer, Beam Ink Multi-Target Research Collaboration For In Vivo Base Editing Programs
Pfizer Inc (NYSE: PFE) and Beam Therapeutics Inc (NASDAQ: BEAM) have announced an exclusive four-year research collaboration focused on in vivo ... 
Via Benzinga
Pfizer Makes Foray Into CRISPR, Inking $1.35 Billion Deal With Beam Therapeutics
The companies hope to cure diseases of the liver, muscle and central nervous system. 
Via Investor's Business Daily
Pfizer and Beam Enter Exclusive Multi-Target Research Collaboration to Advance Novel In Vivo Base Editing Programs for a Range of Rare Diseases
From Pfizer Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2022
Upgrades According to TD Securities, the prior rating for Canada Goose Holdings Inc (NYSE: 
Via Benzinga
Top 5 Moonshots for 2022 Countdown: My No. 5 Pick
2021 wasn't the best year for gene-editing stocks, but expect a comeback in 2022. Here's the top gene-editing choice for next year. 
Via InvestorPlace
Got $1,000? Check Out These 3 Top Biotech Stocks
Two big biotechs and one smaller one that could be winners over the long term. 
Via The Motley Fool
Being First Is Not Enough For Crispr Therapeutics
CRSP stock is facing competition and meeting skepticism as the company tries to turn CRISPR-CAS9 into profitable drug therapies. 
Via InvestorPlace
In Conversation: CMC Markets and ARK Investment Management on the Future of Genomic Testing
Photo by cottonbro from Pexels The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner... 
Via Benzinga
Cathie Wood's Buying Beam Therapeutics -- Should You?
Can this high-flying gene-editing stock keep on climbing for new investors? 
Via The Motley Fool
Looking Into Beam Therapeutics's Return On Capital Employed
Beam Therapeutics (NASDAQ:BEAM) brought in sales totaling $763.00 thousand during Q3 according to data provided by Benzinga Pro. However, earnings decreased 18.08%, resulting in a... 
Via Benzinga
Sana Obtains License To Beam Therapeutics' CRISPR Cas12b Gene Editing Technology
Sana Biotechnology Inc (NASDAQ: SANA) has secured non-exclusive commercial rights to Beam Therapeutics Inc's (NASDAQ: BEAM) CRISPR Cas12b nuclease... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 19, 2021
Upgrades Maxim Group upgraded the previous rating for Indaptus Therapeutics Inc (NASDAQ: 
Via Benzinga
Why Shares of Allogene Therapeutics, Beam Therapeutics, Intellia Therapeutics, and Schrödinger Are Volatile This Week
A key gene-editing readout had Cathie Wood shuffling her portfolio. 
Via The Motley Fool
Exposures Product Safety
Beam Therapeutics Stock Flashes Renewed Technical Strength
On Tuesday, Beam Therapeutics stock reached an key performance benchmark, seeing its RS Rating jump to 92, up from 88 the day before. 
Via Investor's Business Daily
Beam Therapeutics' Base Editors Show Encouraging Preclinical Action In HBV Infection
Beam Therapeutics Inc (NASDAQ: BEAM) has announced preclinical data for its cytosine base editors (CBEs). The data demonstrate the potential of CBEs to reduce... 
Via Benzinga
Beam Therapeutics' Formulated LNP Show Tolerance, Early Storage Stability In Animal Studies
Beam Therapeutics Inc (NASDAQ: BEAM) has announced new preclinical data for novel lipid nanoparticle (LNP) formulations for in vivo liver editing. ... 
Via Benzinga
Beam Therapeutics's Return On Capital Employed Insights
According to data from Benzinga Pro, during Q2, Beam Therapeutics's (NASDAQ:BEAM) reported sales totaled $6.00 thousand. Despite a 70.57% increase in earnings, the company... 
Via Benzinga
The Daily Biotech Pulse: Restricted Authorization For Pfizer's COVID-19 Booster Dose, AbCellera Strikes Antibody Licensing Deal, Solid Biosciences Issues DMD Data
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 22) Acceleron Pharma Inc. (... 
Via Benzinga
Exposures COVID-19
Magenta Therapeutics' Shares Gain As FDA Signs Off Blood Cancer Candidate To Enter Human Trial
The FDA has signed off Magenta Therapeutics Inc's (NASDAQ: MGTA) IND application for MGTA-117. Related Content: Magenta Therapeutics Stock Drops As FDA... 
Via Benzinga
Exposures Product Safety
Could a Recent Gene Editing Breakthrough Make This Cathie Wood Stock a Buy?
One biotech could have the inside track to profit from a major achievement in CRISPR gene editing. 
Via The Motley Fool
Forget About the Genomic Revolution, the Proteomic Revolution Is Coming
Thanks to one small protein sequencing startup, we're entering a new era of proteomics via NGPS technologies that will enable massively parallel protein sequencing. 
Via InvestorPlace
The 3 Best Biotech Stocks to Buy Right Now
Let your portfolio reflect your personality. 
Via The Motley Fool
3 Stocks to Avoid if Cathie Wood's ARK ETF Falls
They likely to do the worst if Michael Burry is right. 
Via The Motley Fool
Why CRISPR Therapeutics, Editas Medicine, and Beam Therapeutics Dropped This Week
After rallying on the coattails of Intelllia's breakthrough, these companies have given back their June gains. 
Via The Motley Fool
WHO Issues Framework For Governance For Gene Editing Technologies
A World Health Organization expert advisory panel Monday issued two new reports recommending the implementation of global standards to prevent future unsafe or... 
Via Benzinga
99 Biggest Movers From Yesterday
Gainers Score Media and Gaming Inc. (NASDAQ: SCR) shares climbed 79.9% to close at $32.64 on Thursday after the company, and Penn National Gaming, announced they entered into a... 
Via Benzinga
A Comprehensive Guide To Genomic ETFs
Given the growing applications of gene-editing, it is a rising market which offers endless opportunities. Growing demand for personalized medicine, solid investments and higher R&D activities will soon... 
Via Talk Markets
Is It Too Late to Buy Intellia Therapeutics?
After skyrocketing 68% last week, will this stock keep running higher? 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.